New, updated, and inactivated tests with detailed information.

View Hotlines


New Tests

View a list of ARUP’s newest additions to the laboratory test directory.

View New Tests



View a list of immediate inactivations in the laboratory test directory.

View Inactivations


Featured New Tests

Next Generation Sequencing

ARUP NGS testing is performed with the patient in mind. Each and every case is carefully reviewed by a Variant Scientist and Medical Director to ensure the report is custom tailored to the patient with the most cutting edge clinical information available.


Prostate Health Index: A More Precise Cancer Screening Test

This FDA-approved test for prostate cancer screening is a multi-analyte blood test that improves the interpretation of an elevated PSA level.

Using an algorithm that calculates the results of three tests into one score, the results provide a more accurate diagnostic evaluation for determining which patients should proceed to biopsy.


Is biopsy the next step? Find out with Prostate Health Index

3000134 Prostate Health Index
  • Recommended in the National Comprehensive Cancer Network (NCCN) guidelines for prostate cancer early detection.
  • In a multicenter study of men with PSA levels between 4 and 10 ng/mL, the Prostate Health Index test was shown to outperform free and total PSA for prostate cancer detection.1
  • New York State Department of Health approved.

Clinical References

1 Loeb S, Catalona WJ: The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 2014 Apr;6(2):74-77.

Secondary Diagnostic For Generalized or Ocular Myasthenia Gravis

Designed for patients with generalized or ocular myasthenia gravis and no detectable antibodies to acetylcholine receptor (AChR).

3001576 Muscle-Specific Kinase (MuSK) Antibody, IgG

This secondary diagnostic test can help clinicians guide treatment, as decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of myasthenia gravis.

Diagnosing CNS Demyelinating Disease or Autoimmune Encephalitis

Useful for initial evaluation of inflammatory CNS demyelinating disease, including neuromyelitis optica spectrum disorder (NMOSD) and NMOSD-like disorders, or autoimmune encephalitis.

3001277 Myelin Oligodendrocyte Glycoprotein (MOG) Antibody, IgG by IFA with Reflex to Titer, Serum
3001283 Autoimmune CNS Demyelinating Disease Reflexive Panel

The presence of myelin oligodendrocyte glycoprotein (MOG) antibody may be associated with neuromyelitis optica spectrum disorders, including optic neuritis and transverse myelitis, brainstem encephalitis, and acute disseminated encephalomyelitis.

This test may be used in monitoring antibody persistence or treatment response in individuals who are antibody positive.

New Oncology Tests: Lymphomas and IHC Stains



3001568 IRF4/DUSP22 (6p25) Gene Rearrangement by FISH

IHC Stains

Used to detect IRF4/DUSP22 rearrangements that can contribute to diagnosis and prognosis in B-cell and T-cell lymphomas.

3001697 Carbonic Anhydrase IX
3001704 Treponema Pallidum
3001562 SOX-10
3001416 Fumarate Hydratase

Updated Pharmacogenetic Tests

Pharmacogenetic testing assesses the risk of abnormal drug metabolism for medications metabolized in specific metabolic pathways.

ARUP has updated our pharmacogenetic tests with new medically relevant genes and variants in our panels.

3001524 Cytochrome P450 Genotyping Panel
3001513 CYP2D6
3001508 CYP2C19
3001501 CYP2C8 and CYP2C9
3001518 CYP3A4 and CYP3A5
3001535 TPMT and NUDT15
3001541 Warfarin Sensitivity (CYP2C8, CYP2C9, CYP4F2, VKORC1) Genotyping

Pharmacogenetic testing provides an opportunity to lower the cost of adverse drug events by:

  • Preventing many adverse drug events before they occur.
  • Reducing pharmacy costs for clients by optimizing dosage.
  • Decreasing the number of patient hospitalizations.
  • Improving patient compliance with their drug therapies.